The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Microbial Immunology
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1439176
Safety and Efficacy of Fecal Microbiota Transplantation (FMT) as Modern Adjuvant Therapy in Various Diseases and Disorders: A Comprehensive Literature Review
Provisionally accepted- 1 Bogomolets National Medical University, Kyiv, Ukraine
- 2 Hamadan University of Medical Sciences, Hamedan, Iran
- 3 School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
- 4 Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 5 Department of Veterinary Medicine, Islamic Azad University of Urmia, Urmia, Iran
- 6 Student Research Committee, Arak University of Medical Sciences, Arak, Markazi, Iran
- 7 Internal Medicine Department, Tehran University of Medical Sciences (TUMS), Tehran, Iran
The human gastrointestinal (GI) tract microbiome is a complex and all-encompassing ecological system of trillions of microorganisms. It plays a vital role in digestion, disease prevention, and overall health. When this delicate balance is disrupted, it can lead to various health issues. Fecal microbiota transplantation (FMT) is an emerging therapeutic intervention used as an adjuvant therapy for many diseases, particularly those with dysbiosis as their underlying cause. Its goal is to restore this balance by transferring fecal material from healthy donors to the recipients. FMT has an impressive reported cure rate between 80% and 90% and has become a favored treatment for many diseases. While FMT may have generally mild to moderate transient adverse effects, rare severe complications underscore the importance of rigorous donor screening and standardized administration. FMT has enormous potential as a practical therapeutic approach; however, additional research is required to further determine its potential for clinical utilization, as well as its safety and efficiency in different patient populations. This comprehensive literature review offers increased confidence in the safety and effectiveness of FMT for several diseases affecting the intestines and other systems, including diabetes, obesity, inflammatory and autoimmune illness, and other conditions.
Keywords: fecal microbiota transplantation, fecal transplantation, microbiota, Dysbiosis,, gut microbiome, Immunomodulation, adjuvant therapy
Received: 28 May 2024; Accepted: 09 Sep 2024.
Copyright: © 2024 Karimi, Shirsalimi, Hashempour, Salehi Omran, Sedighi, Beigi and Mortezazadeh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mehdi Karimi, Bogomolets National Medical University, Kyiv, Ukraine
Niyousha Shirsalimi, Hamadan University of Medical Sciences, Hamedan, Iran
Farzan Beigi, Student Research Committee, Arak University of Medical Sciences, Arak, Markazi, Iran
Masoud Mortezazadeh, Internal Medicine Department, Tehran University of Medical Sciences (TUMS), Tehran, Iran
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.